Metoprolol Tartrate API
Metoprolol tartrate is a cardioselective β₁-adrenergic blocker (beta‐blocker) salt used in cardiovascular therapy. In its active pharmaceutical ingredient form, it appears as a white, crystalline powder (molecular weight ≈684.82 g/mol). The powder is very soluble in water (also soluble in organic solvents like methylene chloride and alcohol). (According to USP, it is not hygroscopic but is light-sensitive, so should be stored protected from strong light.
Metoprolol Tartrate USP For Compounding (API) is a beta-blocker used primarily for managing cardiovascular conditions, including hypertension (high blood pressure), angina (chest pain), and arrhythmias (irregular heartbeats). By blocking beta-adrenergic receptors in the heart, it reduces heart rate, cardiac output, and blood pressure, thereby decreasing the heart's oxygen demand and improving heart health. This active pharmaceutical ingredient is essential for creating customized formulations that cater to individual patient needs, ensuring precise dosing and optimal therapeutic outcomes. It plays a crucial role in cardiovascular health, blood pressure management, and prevention of heart disease complications.
Metoprolol tartrate USP is an active pharmaceutical ingredient (API) used in the manufacturing of prescription medications for the treatment of high blood pressure, angina, and heart failure. It belongs to a class of drugs known as beta-blockers, which work by blocking the effects of adrenaline on the heart and blood vessels. This helps to lower blood pressure, improve blood flow, and reduce strain on the heart. Metoprolol tartrate USP comes in the form of tablets or injections and is commonly used in combination with other medications to treat various cardiovascular conditions.
Mechanism of Action: Metoprolol selectively antagonizes β₁‐adrenergic receptors primarily in heart muscle. This leads to reduced heart rate (negative chronotropy), decreased myocardial contractility (negative inotropy), and lower cardiac output, thereby lowering blood pressure and myocardial oxygen demand. In hypertension, additional mechanisms include central sympatholysis and reduced renin release. At higher plasma levels, metoprolol can also block β₂ receptors in bronchial and vascular smooth muscle, so selectivity is dose-dependent. Unlike some beta-blockers, metoprolol has no intrinsic sympathomimetic activity.
Indications/Uses: Metoprolol tartrate is indicated for hypertension, chronic stable angina pectoris, and the management of acute myocardial infarction (to reduce mortality when used with IV therapy). It improves survival following heart attacks and is part of post-MI therapy. It is also used (often off-label) for certain arrhythmias (e.g. supraventricular tachycardia), congestive heart failure (as part of combination therapy), hyperthyroidism (symptom control), and migraine prophylaxis. Lowering blood pressure with metoprolol (alone or in combination) reduces risks of stroke and myocardial infarction.
Administration and Dosing: Metoprolol tartrate is administered orally. Immediate-release tablets (commonly 25, 50, 100 mg) are usually taken in 1–2 divided doses per day. A typical starting dose for hypertension or angina in adults is around 50–100 mg per day, often given as 25–50 mg twice daily. Doses may be titrated up (sometimes to 200–400 mg/day in resistant cases). (For example, one source recommends 100 mg/day as a starting dose for hypertension.) In myocardial infarction, IV metoprolol can be given as needed under monitoring, followed by oral dosing (often 50 mg every 6 hours). The duration of action of a metoprolol dose is dose-dependent (50% effect loss in ~3–6 hours), so immediate-release tartrate often requires twice-daily dosing. (By contrast, metoprolol succinate is an extended-release once-daily formulation; tartrate and succinate salts are not interchangeable.)
Pharmacokinetics: Metoprolol is well absorbed (≈50% bioavailability after a single dose, increasing with repeated dosing and has a half-life of about 3–7 hours. It is extensively metabolized by the liver (CYP2D6 and CYP3A4), resulting in inactive metabolites; only about 10–20% of a dose is excreted unchanged in urine. Because of first-pass metabolism, blood levels can vary; dosing should be individualized. It is only ~12% protein-bound. Metoprolol crosses the placenta (pregnancy category C) and is present in breast milk, though it appears relatively safe in nursing mothers.
Side Effects: Common side effects arise from excess β₁-blockade: bradycardia, hypotension, dizziness/lightheadedness (especially upon standing), fatigue, headache, and gastrointestinal upset (nausea, diarrhea) are frequently reported. Patients may experience cold extremities or peripheral vasoconstriction, and some (especially men) report sexual dysfunction (decreased libido/impotence). Central nervous system effects like depression, vivid dreams or insomnia can occur. Because of slowed heart rate, exercise tolerance may decrease and chest heaviness can paradoxically worsen if dosage is too high or withdrawn suddenly. In asthmatic/COPD patients, broncho-constriction (wheezing) is possible because high doses block β₂- receptors. Severe side effects (uncommon) include profound bradyarrhythmias or heart block, heart failure exacerbation, and severe hypotension. Overdose can lead to life-threatening bradycardia, hypotension, bronchospasm and cardiogenic shock.
Contraindications & Precautions: Metoprolol tartrate should not be used in patients with severe sinus bradycardia, 2nd or 3rd degree AV block (unless paced), sick sinus syndrome, cardiogenic shock, or decompensated heart failure. Caution is required in patients with asthma or chronic pulmonary disease (risk of bronchospasm) and in markedly slow heart rhythms or hypotension. In pheochromocytoma, β-blockers must be given only after adequate α-blockade, to avoid unopposed α-adrenergic hypertension. In diabetics, metoprolol can mask tachycardia and other adrenergic symptoms of hypoglycemia. It also masks hyperthyroid symptoms, so thyroid storm risk is increased on abrupt withdrawal. Patients should be warned not to stop metoprolol suddenly; abrupt withdrawal can precipitate angina, arrhythmias, or myocardial infarction, especially in ischemic heart disease. Other cautions: use lower doses in the elderly or those with liver impairment, and monitor electrolytes in heart failure. Metoprolol can interact with other antihypertensives (additive effects) and with CYP2D6 inhibitors (which can raise metoprolol levels).
Formulations: Metoprolol tartrate oral tablets are available in multiple strengths (25–100 mg). Tablets contain inert fillers (lactose, cellulose, etc.) and colorants. No injectable tartrate is commonly used; injectable metoprolol as a solution is usually the succinate form. For manufacturing, bulk metoprolol tartrate API is made to USP standards (white, crystalline, odorless powder). It is stable at room temperature (15–25 °C). (By contrast, metoprolol succinate is the extended-release salt used in long-acting tablets.) While tartrate (Lopressor) and succinate (Toprol-XL) are chemically related, they are not bioequivalent – dosing regimens differ.
Key Points: Metoprolol tartrate is a commonly prescribed β₁-selective blocker for hypertension, angina, and post-MI management. It lowers heart rate and blood pressure by blocking cardiac β₁ receptors. It must be dosed carefully (often twice daily for the tartrate salt) and tapered slowly on discontinuation. Main risks include bradycardia, hypotension, and bronchospasm; serious effects are uncommon with proper monitoring. As with all drugs, use according to guidelines and monitor the patient for therapeutic response and adverse effects.
This overview is based on standard pharmaceutical references and FDA-approved labeling for metoprolol tartrate. For complete prescribing information, consult official drug monographs.
